

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM330506

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Response Genetics, Inc.		07/30/2014	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	SWK Funding LLC, as Agent		
<b>Street Address:</b>	15770 North Dallas Parkway, Suite 1290		
<b>City:</b>	Dallas		
<b>State/Country:</b>	TEXAS		
<b>Postal Code:</b>	75248		
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE		
<b>PROPERTY NUMBERS Total: 14</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2800637		
<b>Registration Number:</b>	2800718	RESPONSE GENETICS	
<b>Serial Number:</b>	86107818	RESPONSEDX: TISSUE OF ORIGIN	
<b>Serial Number:</b>	86062818	RESPONSEDX: TOO	
<b>Serial Number:</b>	86061652	RESPONSE GENETICS	
<b>Serial Number:</b>	85330476	RESPONSEDX: MELANOMA	
<b>Serial Number:</b>	77982239	RESPONSEDX	
<b>Serial Number:</b>	77768260	RESPONSEDX: GASTRIC	
<b>Serial Number:</b>	77587739	THE RIGHT THERAPY FOR EACH PATIENT THE F	
<b>Serial Number:</b>	77587737	KRAS IS ONLY HALF THE EQUATION	
<b>Serial Number:</b>	77381028	RESPONSEDX	
<b>Serial Number:</b>	77386502	BECAUSE EVERYONE HAS A DIFFERENT RESPONS	
<b>Serial Number:</b>	77381017	RESPONSEDX: LUNG	
<b>Serial Number:</b>	77381009	RESPONSEDX: COLON	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2149649501		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	214.964.9459		

OP \$365.00 2800637

**Email:** ryan.magee@hklaw.com  
**Correspondent Name:** Ryan Magee  
**Address Line 1:** Holland & Knight LLP  
**Address Line 2:** 200 Crescent Court, Suite 1600  
**Address Line 4:** Dallas, TEXAS 75201

**ATTORNEY DOCKET NUMBER:** 136144.00015/MADREWS

**NAME OF SUBMITTER:** Ryan Magee

**SIGNATURE:** /Ryan Magee/

**DATE SIGNED:** 01/29/2015

**Total Attachments: 26**

source=Response Genetics = Intellectual Property Security Agreement#page1.tif  
source=Response Genetics = Intellectual Property Security Agreement#page2.tif  
source=Response Genetics = Intellectual Property Security Agreement#page3.tif  
source=Response Genetics = Intellectual Property Security Agreement#page4.tif  
source=Response Genetics = Intellectual Property Security Agreement#page5.tif  
source=Response Genetics = Intellectual Property Security Agreement#page6.tif  
source=Response Genetics = Intellectual Property Security Agreement#page7.tif  
source=Response Genetics = Intellectual Property Security Agreement#page8.tif  
source=Response Genetics = Intellectual Property Security Agreement#page9.tif  
source=Response Genetics = Intellectual Property Security Agreement#page10.tif  
source=Response Genetics = Intellectual Property Security Agreement#page11.tif  
source=Response Genetics = Intellectual Property Security Agreement#page12.tif  
source=Response Genetics = Intellectual Property Security Agreement#page13.tif  
source=Response Genetics = Intellectual Property Security Agreement#page14.tif  
source=Response Genetics = Intellectual Property Security Agreement#page15.tif  
source=Response Genetics = Intellectual Property Security Agreement#page16.tif  
source=Response Genetics = Intellectual Property Security Agreement#page17.tif  
source=Response Genetics = Intellectual Property Security Agreement#page18.tif  
source=Response Genetics = Intellectual Property Security Agreement#page19.tif  
source=Response Genetics = Intellectual Property Security Agreement#page20.tif  
source=Response Genetics = Intellectual Property Security Agreement#page21.tif  
source=Response Genetics = Intellectual Property Security Agreement#page22.tif  
source=Response Genetics = Intellectual Property Security Agreement#page23.tif  
source=Response Genetics = Intellectual Property Security Agreement#page24.tif  
source=Response Genetics = Intellectual Property Security Agreement#page25.tif  
source=Response Genetics = Intellectual Property Security Agreement#page26.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of July 30, 2014 (as may be amended, restated, supplemented, or otherwise modified from time to time, this “**Agreement**”), made by RESPONSE GENETICS, INC., a Delaware corporation (“**Borrower**”), in favor of SWK FUNDING LLC, a Delaware limited liability company, as collateral agent (in such capacity, “**Agent**”) for the Lenders (as defined below) party to the Credit Agreement (as defined below).

### **W I T N E S S E T H:**

WHEREAS, pursuant to that certain Credit Agreement, dated on or about the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), by and among Borrower, Agent and the financial institutions party thereto from time to time as lenders (each a “**Lender**” and collectively, the “**Lenders**”), Agent and Lenders have agreed to make certain financial accommodations available to Borrower, and Borrower has granted a security interest to Agent, for the benefit of Lenders, in, among other things, all right, title and interest of Borrower in, to and under all of Borrower’s Intellectual Property (as defined below), whether now existing or hereafter arising or acquired as security for the Obligations; and

WHEREAS, Borrower has an ownership or license interest in, to and under the Intellectual Property listed on Schedule I hereto.

NOW, THEREFORE, in consideration of the premises and to induce Agent and Lenders to enter into the Credit Agreement, Borrower hereby agrees with Agent as follows:

#### **1. Defined Terms.**

(a) Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement.

(b) Definitions of Certain Terms Used Herein. As used herein, the following terms shall have the following meanings:

“**Copyrights**” shall mean all of Borrower’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title, and interest in and to: (i) copyrights, rights and interests in copyrights, works protectable by copyright, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Copyright Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) all renewals of any of the foregoing.

“**Copyright Licenses**” shall mean all written agreements naming the Borrower as licensor or licensee, granting any right under any Copyright, including the grant of rights to manufacture, distribute, exploit and sell materials derived from any Copyright (other than agreements relating to widely-available software subject to “shrink-wrap” or “click-through” software licenses).

“**Credit Agreement**” shall have the meaning assigned to such term in the recitals of this Agreement.

**“Intellectual Property”** shall mean all present and future: trade secrets, know-how and other proprietary information; Trademarks, internet domain names, service marks, trade dress, trade names, business names, designs, logos, slogans (and all translations, adaptations, derivations and combinations of the foregoing) indicia and other source and/or business identifiers, and the goodwill of the business relating thereto and all registrations or applications for registrations which have heretofore been or may hereafter be issued thereon throughout the world; Copyrights (including Copyrights for computer programs, but excluding commercially available off-the-shelf software and any Intellectual Property rights relating thereto) and all tangible and intangible property embodying the Copyrights, unpatented inventions (whether or not patentable); Patents; industrial design applications and registered industrial designs; license agreements related to any of the foregoing and income therefrom, books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases and other physical manifestations, embodiments or incorporations of any of the foregoing; the right to sue for all past, present and future infringements of any of the foregoing; all other intellectual property; and all common law and other rights throughout the world in and to all of the foregoing.

**“IP Collateral”** shall have the meaning assigned to such term in Section 2 hereof.

**“Licenses”** shall mean, collectively, the Trademark Licenses, the Patent Licenses, and the Copyright Licenses.

**“Patents”** shall mean all of Borrower’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title and interest in and to: (i) all patents, patent applications, inventions, invention disclosures and improvements, and all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) the reissues, divisions, continuations, renewals, extensions and continuations-in-part of any of the foregoing.

**“Patent Licenses”** shall mean all agreements, whether written or oral, providing for the grant by or to Borrower of any right to manufacture, develop, market, use or sell any products derived, in whole or in part, from any invention covered by a Patent or any similar agreement related to any other use of any invention covered by a Patent.

**“Trademarks”** shall mean all of Borrower’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title, and interest in and to: (i) all of Borrower’s (or if referring to another Person, such other Person’s) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, other business identifiers, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; (ii) all renewals thereof; and (iii) all designs and general intangibles of a like nature.

**“Trademark Licenses”** shall mean, collectively, each agreement, whether written or oral, providing for the grant by or to Borrower of any right to use any Trademark.

(c) **Other Definitional Provisions.**

(i) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and paragraph references are to this Agreement unless otherwise specified.

(ii) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

**2. Grant of Security Interest**To secure the payment and performance of the Obligations, Borrower hereby confirms and acknowledges that it has granted (and, to the extent not previously granted under the Guarantee and Collateral Agreement, does hereby grant) to Agent, for the benefit of Lenders, a lien and security interest in Borrower’s entire right, title and interest in its Intellectual Property and all proprietary rights relating to or arising from such Intellectual Property, in each case whether now owned or hereafter acquired by Borrower, and including, without limitation, Borrower’s right, title and interest in and to the Intellectual Property and proprietary rights identified on Schedule I attached hereto and made a part hereof, and the right to sue for past, present and future infringements and dilutions, and all rights corresponding thereto throughout the world, and the entire goodwill of Borrower’s business connected with and symbolized by such Intellectual Property and all income, fees, royalties, proceeds and other payments at any time due or payable with respect to any of the foregoing (referred to collectively as the “**IP Collateral**”); provided, that the IP Collateral shall not include the Excluded Property (as defined in the Guarantee and Collateral Agreement).

**3. Protection of Intellectual Property by Borrower**Borrower shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section 5.7 of the Guarantee and Collateral Agreement in respect to the Intellectual Property.

**4. Representations and Warranties**Borrower represents and warrants that:

(a) Schedule I is a true, correct and complete list of all registered or applied-for Intellectual Property in which Borrower purports to have an ownership or license interest.

(b) Borrower has the legal right and authority to enter into this Agreement and perform its terms.

(c) If Borrower amends its name, Borrower shall provide copies of such amendment documentation to Agent and shall re-register Borrower’s Intellectual Property with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall request to maintain a perfected first priority security interest in such Intellectual Property subject to Permitted Liens.

**5. No Violation of Credit Agreement**The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

**6. Agreement Applies to Future Intellectual Property.**

(a) The provisions of this Agreement shall automatically apply to any such additional property or rights described in Section 2 above, all of which shall be deemed to be and treated as "IP Collateral" within the meaning of this Agreement.

(b) Upon the request of Agent, Borrower shall execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as Agent may reasonably request to evidence Agent's security interest in any IP Collateral and the goodwill of Borrower relating thereto or represented thereby (including, without limitation, filings with the United States Patent and Trademark Office or any similar office), and Borrower hereby constitutes Agent as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed; provided, however, that Agent's taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

**7. Borrower's Rights to Enforce Intellectual Property** Prior to Agent's giving of notice to Borrower following the occurrence and during the continuance of an Event of Default, Borrower shall have the exclusive right to sue for past, present and future infringement of the IP Collateral, including the right to seek injunctions and/or money damages, in an effort by Borrower to protect the IP Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by Borrower on account of such suit (or the threat of such suit) shall constitute IP Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys' fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guarantee and Collateral Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to Borrower may terminate or limit Borrower's rights under this Section 7.

**8. Agent's Actions to Protect Intellectual Property** Pursuant to and in accordance with the Credit Agreement, Agent, acting in its own name or in that of Borrower, may (but shall not be required to) act in Borrower's place and stead and/or in Agent's own right with respect to the rights and obligations of Borrower under Section 3, Section 6 and Section 7 hereof.

**9. Rights Upon Default.** Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Credit Agreement.

**10. Agent as Attorney In Fact.**

(a) Borrower hereby irrevocably constitutes and designates Agent as its attorney-in-fact to:

(i) Following the occurrence and during the continuance of an Event of Default, supplement and amend from time to time Schedule I of this Agreement to include any new or additional Intellectual Property of Borrower.

(ii) Exercise any of the rights and powers referenced herein in accordance with this Agreement.

- (b) The grant of a power of attorney, being coupled with an interest, shall be irrevocable until the Obligations are paid in full.
- (c) Agent shall not be obligated to do any of the acts or to exercise any of the powers authorized by Section 8, Section 9 or Section 10 of this Agreement, but if Agent elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such exercise of power, and shall not be responsible to Borrower for any act or omission to act, except to the extent Agent acted with gross negligence or willful misconduct as determined by a court of competent jurisdiction.

11. **Agent's Rights** Upon an Event of Default and during the continuance thereof, any use by Agent of the IP Collateral, as authorized hereunder in connection with the exercise of Agent's rights and remedies under this Agreement and under the Credit Agreement shall be coextensive with Borrower's rights thereunder and with respect thereto and without any liability for royalties or other related charges.

12. **No Limitation; Loan Documents** This Agreement has been executed and delivered by Borrower for the purpose of recording the security interest granted to Agent with respect to the IP Collateral with the United States Patent and Trademark Office, the United States Copyright Office, as well as with any similar office or department of any other foreign or domestic Governmental Authority. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of Lender, under the Guarantee and Collateral Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Borrower, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with its terms.

13. **Termination; Release of Trademark Collateral** This Agreement and all obligations of Borrower and Agent hereunder shall terminate on the date upon which the Obligations are performed in full and paid in full. Upon termination of this Agreement, Agent shall, at the expense of the Borrower, take such actions required by the Credit Agreement or the Guarantee and Collateral Agreement or as otherwise reasonably requested by Borrower to release its security interest in the IP Collateral.

14. **Binding Effect; Benefits** This Agreement shall be binding upon Borrower and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

15. **GOVERNING LAW.**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ITS CHOICE OF LAW PROVISIONS THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

16. **Copy of Agreement** Borrower acknowledges receipt of a signed copy of this Agreement.

*[Remainder of page intentionally blank; signature page follows.]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be executed by its duly authorized representatives as of the date first above written.

**BORROWER:**

**RESPONSE GENETICS, INC.,**  
a Delaware corporation

By:   
Name: Thomas A. Bologna  
Title: Chief Executive Officer

[Signature Page to Intellectual Property Security Agreement]

#31712882

**TRADEMARK**  
**REEL: 005449 FRAME: 0655**



**AGENT:**

**SWK FUNDING LLC,**  
a Delaware limited liability company

By:   
Name: Winston Black  
Title: Managing Director

[Signature Page to Intellectual Property Security Agreement]

#31712882

**TRADEMARK**  
**REEL: 005449 FRAME: 0656**

## Schedule I

### Copyrights

Description	Registration/ Application Number	Registration/ Application Date
NONE		

### Patents

#### Patent Family: ERCC1 and cisplatin

##### U.S. cases:

Ref. No.	Application No./ Description	Status	Title
11220/118	09/796,491, filed March 2, 2001	U.S. Patent No. 6,518,416, issued February 11, 2003.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/127	09/877,095, filed June 6, 2001, a continuation-in-part of 09/796,491 (Matter 118), filed March 2, 2001	U.S. Patent No. 6,573,052, issued June 3, 2003.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/145	09/988,784, filed November 20, 2001, continuation-in-part of 09/877,095, filed June 6, 2001, which is a continuation-in-part of 09/796,491, filed March 2, 2001	U.S. Patent No. 6,602,670, issued August 5, 2003.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/197	10/453,784, filed June 4, 2003, a continuation of 09/988,784, filed November 20, 2001, which is a continuation-in-part of 09/877,095, filed June 6, 2001, which is a continuation-in-part of 09/796,491, filed March 2, 2001	U.S. Patent No. 7,132,238, issued November 7, 2006 <a href="http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITO&amp;FF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=7132238.PN.&amp;OS=PN/7132238&amp;RS=PN/7132238-h0#h0">http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITO&amp;FF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=7132238.PN.&amp;OS=PN/7132238&amp;RS=PN/7132238-h2#h2</a>	Method of determining a chemotherapeutic regimen based on ERCC1 expression

##### Foreign Cases:

Ref. No.	Description/Application No.	Status	Title
11220/133	Taiwan – 90129673, filed November 30, 2001	Patent No. I321155, granted March 1, 2010.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/134	PCT/US01/44519, filed November	Application Publication No.	Method of determining a

Ref. No.	Description/Application No.	Status	Title
	29, 2001	WO 02/061128	chemotherapeutic regimen based on ERCC1 expression
11220/184	Australia – 2002249768, filed November 29, 2001	Patent No. 2002249768 B2, granted April 19, 2007.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/185	Canada – 2437044, filed November 29, 2001	Patent No. 2,437,044, granted March 12, 2013	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/186	China - 01822442.3, filed November 29, 2001	Patent No. ZL01822442.3 granted March 7, 2012.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/187	EP - 01998006.9, filed November 29, 2001	Publication No. 1364054. Accepted for grant on April 14, 2013.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/248	Hong Kong - 05110187.7, filed November 29, 2001	Patent No. 1078328B, granted September 14, 2012.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/188	Japan – 2002-561063, filed November 29, 2001	Patent No. 4503922, granted April 30, 2010.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/189	Korea - 10-2003-7007375, filed November 29, 2001	Patent No.: 10-966271, granted June 18, 2010.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/291	Korea – Application No. 2009-7026317, DIV of Korea - 10-2003-7007375 (11220/189)	Patent No. 10-1014345, granted February 7, 2011.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/190	Mexico - PA/A/2003/004930, filed November 29, 2001	Patent No. 287966, granted July 01, 2011	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/195	Israel – 156272, filed November 29, 2001	Allowed in November 2013.	Method of determining the level of ERCC1 expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament
11220/302	Israel: 215130, filed September 13, 2011  Div of 11220/195 (Israel – 156272)	Pending.	Method of determining a chemotherapeutic regimen based on ERCC1 expression
11220/196	New Zealand - 526710, filed November 29, 2001	NZ Patent No. 526710, granted January 12, 2006.	Method of determining a chemotherapeutic regimen based on ERCC1 expression

**Patent Family: EGFR and Her-2-neu**

**U.S. cases:**

Ref. No.	Description/ Application No.	Status	Title
11220/120	09/877,177, filed June 11, 2001.	U.S. Patent No. 6,582,919, issued June 24, 2003.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates

**Foreign cases:**

Ref. No.	Description/ Application No.	Status	Title
11220/143	Taiwan – 90129662, filed November 30, 2001	Patent No. I313711, granted August 21, 2009.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/277	ROC (Taiwanese) Application No. 097112520, filed March 23, 2008 DIV of Taiwan – 90129662 (11220/143)	Patent No.: I312809, granted August 1, 2009.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/278	ROC (Taiwanese) Application No. 097112522, filed March 21, 2008 DIV of Taiwan – 90129662 (11220/143)	Patent Certificate No. I321156, issued March 1, 2010.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/144	PCT/US01/43035, filed November 9, 2001	Application Publication No. WO 02/44413	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/170	Australia -2002232409, filed November 9, 2001	Patent No.: 2002232409, granted March 22, 2007.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/171	Canada – 2436910, filed November 9, 2001	Allowed. Publication No. 2436910	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/173	Europe - 01991929.9, filed November 9, 2001	European Patent No. 1379686, granted September 5, 2012.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates

Ref. No.	Description/ Application No.	Status	Title
11220/283	Japan - 2009-000427, filed January 5, 2009 DIV of Japan - 2002-546761 (1120/174)	Patent No. 4510915, granted May 14, 2010.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/175	Korean Application No. 10-2003-7007378, , filed November 9, 2001	Patent No. 10-946980, granted March 4, 2010.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/286	Korean Application No. 2009-7018726, filed September 8, 2009 DIV of 10-2003-7007378 (11220/175)	Patent No. 10-1014342, granted February 7, 2011.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/296	Korean- 10-2010-7019342 filed August 31, 2010. DIV of Korean Application No. 2009-7018726 (11220/286)	Pending. Publication number unknown.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/176	Mexico - PA/A/2003/004929, , filed November 9, 2001	Patent No. 282866, granted January 14, 2011.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/276	Mexico – MX/a/2008/005896, filed March 2, 2008 DIV of PA/A/2003/004929 (11220/176)	Patent No. 293677, granted December 14, 2011.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/191	Israel - 156233, filed November 9, 2001	Patent No. 156233, granted July 30, 2010.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/282	Application No. 195460, filed November 23, 2008 DIV of Israel – 156233 (11220/191)	Patent No.: 156233, granted on December 1, 2012.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/192	New Zealand - 526709, filed November 9, 2001	New Zealand Patent No. 526709, granted September 11, 2008. Declaration re restoration filed June 14, 2011.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates
11220/260	New Zealand – 546251, filed March 30, 2006 DIV of 11220/192; New Zealand - 526709	New Zealand Patent No. 546251, granted May 15, 2008.	Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels

Ref. No.	Description/ Application No.	Status	Title
11220/261	New Zealand – 546252, filed March 28, 2006  DIV of 11220/192; New Zealand - 526709	New Zealand Patent No. 546252, granted July 10, 2008.	Thereofwith Survival Rates Methods of Determining Epidermal Growth Factor Receptor and Her2-Neu Gene Expression and Correlation of Levels Thereofwith Survival Rates



Ref. No.	Description/ Application No./Patent No.	Status	Title
	November 9, 2001	granted July 19, 2007.	chemotherapeutic regimen based on ERCC1 and TS expression
11220/178	Canada - 2437038, filed November 9, 2001	Allowed. Publication No. 2437038	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/179	China - 01822464.4, filed November 9, 2001	Patent No. ZL01822464.4, granted June 22, 2011.	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/180	Europe - 01994073.3, filed November 9, 2001	European Patent No. 1381691, granted April 24, 2013.	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/181	Japan - 2002-558541, filed November 9, 2001	To be abandoned. Publication No. 2004-535771	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/295	Japan- 2010-177164, filed August 6, 2010. DIV of Japan - 2002-558541 (11220/181)	Pending. Publication No. 2011-004756	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/183	Mexico - PA/A/2003/004928, filed November 9, 2001	Mexican Patent No. 264888, granted March 3, 2009.	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/193	Israel - 156232, filed November 9, 2001	Patent No. 156232, granted October 1, 2010.	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
11220/194	New Zealand - 526711, filed November 9, 2001	Patent No. 526711, granted December 14, 2006.	Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression



**Patent Family: Chemotherapy and Gene Expression in Primary Tumors**

**U.S. cases:**

<b>Ref. No.</b>	<b>Description/ Application No./Patent No.</b>	<b>Status</b>	<b>Title</b>
11220/269	11/731,128, filed March 30, 2007, a divisional of 09/998,333, filed December 3, 2001	Patent No. 8,026,062, issued September 27, 2011.	Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors

**Foreign case:**

<b>Ref. No.</b>	<b>Description/ Application No./Patent No.</b>	<b>Status</b>	<b>Title</b>
11220/147	Taiwan - 90/129809 filed December 3, 2001	Patent No.: I319010, granted January 1, 2010.	Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors

## Patent Family: Method of Determining Dihydropyrimidine Dehydrogenase Gene Expression

### U.S. cases:

Ref. No.	Description/ Application No./Patent No.	Status	Title
11220/117	09/796,807, filed March 2, 2001	U.S. Patent No. 6,956,111 issued October 18, 2005.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/128	09/842,111 filed April 26, 2001, continuation-in-part of 09/796,807 (Matter 117), filed March 2, 2001	U.S. Patent No. 6,905,821, issued June 14, 2005.	Method of determining dihydropyrimidine dehydrogenase gene expression
1122/129	09/879,217, filed June 13, 2001, a continuation-in-part of 09/842,111 (Matter 128), filed April 26, 2001, which is a continuation-in-part of 09/796,807 (Matter 117), filed March 2, 2001	U.S. Pat No. <a href="http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITO&amp;FF&amp;d=PALL&amp;p=1&amp;u=%2Fnetacgml%2FFPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=7005278.PN.&amp;OS=PN/7005278&amp;RS=PN/7005278-h0#h0">http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITO&amp;FF&amp;d=PALL&amp;p=1&amp;u=%2Fnetacgml%2FFPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=7005278.PN.&amp;OS=PN/7005278&amp;RS=PN/7005278-h0#h0</a> <a href="http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITO&amp;FF&amp;d=PALL&amp;p=1&amp;u=%2Fnetacgml%2FFPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=7005278.PN.&amp;OS=PN/7005278&amp;RS=PN/7005278-h2#h2">http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITO&amp;FF&amp;d=PALL&amp;p=1&amp;u=%2Fnetacgml%2FFPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=7005278.PN.&amp;OS=PN/7005278&amp;RS=PN/7005278-h2#h2</a> 7,005,278, issued February 28, 2006.	Method of determining dihydropyrimidine dehydrogenase gene expression

### Foreign cases:

Ref. No.	Description/ Application No./Patent No.	Status	Title
11220/156	Argentina - P020100723, filed February 28, 2002	Patent No.: AR032917, granted April 30, 2010.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/157	Taiwan - 91103764, filed March 1, 2002	Patent No.: I274076, granted February 21, 2007.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/155	PCT/US02/05221, filed February 22, 2002	Application Publication No. WO 02/070750	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/199	Australia - 2002 238115, filed February 22, 2002	Australian Patent No. 2002238115, issued September 27, 2007.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/200	Canada - 2439313, filed February 22, 2002	Patent No. 2439313, granted August 7, 2012.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/201	China - 02809318.6, filed February 22, 2002	Chinese Patent No. ZL02809318.6, granted April 12, 2006.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/257	China - 200610007076.2, filed February 10, 2006  Divisional of 02809318.6 (11220/201)	Patent No. ZL200610007076.2, granted October 6, 2010.	Method of determining dihydropyrimidine dehydrogenase gene expression

Ref. No.	Description/ Application No./Patent No.	Status	Title
11220/270	Hong-Kong--07103601.8, filed February 22, 2002 Based on the Chinese Patent Application No. 200610007076.2 (11220/257)	Patent No. HK1097571, granted August 5, 2011	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/258	China - 200610007077.7, filed February 10, 2006 Divisional of 02809318.6 (11220/201)	Patent No. ZL200610007077.7, granted December 8, 2010.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/272	Hong Kong--07103602.7 Based on 200610007077.7 (11220/258), which has been granted December 8, 2010.	Patent No. HK1097575, granted on September 2, 2011.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/202	Europe - 02704432.0, filed February 22, 2002	EP Patent 1 409 723 B1, granted August 18, 2006.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/203	Israel -157694, filed February 22, 2002	Patent No. 157694, granted March 1, 2011.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/236	Hong Kong Based on Chinese Patent Application No. 02809318.6 (11220/201)	Patent No. HK1068375, granted October 27, 2006.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/284	Japan -2008-278350, filed October 29, 2008 DIV of 2002-570772 (11220/204)	Patent No. 4690446, granted February 25, 2011.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/298	Japan- 2010-278407, filed December 14, 2010. DIV of JP 2008-278350 (11220/284)	Pending. Publication number unknown.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/205	Korea - 10-2003-7011484, filed February 22, 2002	Korean Patent No. 10-909116, issued July 16, 2009.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/206	Mexico - PA/A/2003/007884, filed February 22, 2002	Mexican Patent No. 254799, granted February 15, 2008.	Method of determining dihydropyrimidine dehydrogenase gene expression
11220/207	New Zealand - 528374, filed February 22, 2002	New Zealand Patent No. 528374, granted May 15, 2008.	Method of determining dihydropyrimidine dehydrogenase gene expression

## Patent Family: Method of Determining a Chemotherapeutic Regimen Based on *GST-pi* Expression

### U.S. cases:

Ref. No.	Description/ Application No./Patent No.	Status	Title
11220/131	09/879,986, filed June 14, 2001	U.S. Patent No. 6,686,155, issued February 3, 2004.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/212	10/654,575, filed September 4, 2003, a divisional of 09/879,986 (Matter 131), filed June 14, 2001	U.S. Patent No. 7,138,507, issued November 21, 2006.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression

### Foreign cases:

Ref. No.	Description/ Application No./Patent No.	Status	Title
11220/160	Argentina - P02010954, filed May 24, 2002	Patent No. AR034342, granted January 30, 2012.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/161	Taiwan – 9111310, filed May 28, 2002	Patent No.: I338049, granted March 1, 2011.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/159	PCT/US02/15203, filed May 15, 2002	Application Publication No. WO 02/103055	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/218	Australia – 2002305573 (national phase of 11220/159) , filed May 15, 2002	Australian Patent No. 2002305573, granted April 23, 2009.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/219	Canada – 2450257, filed May 15, 2002	Patent No. 2450257, granted November 6, 2012.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/220	China – 02815798.2, filed May 15, 2002 (national phase of 11220/159)	Patent No. ZL02815798.2, granted June 3, 2009.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/251	China - 200510107684.6, filed September 26, 2005, a divisional of 02815798.2 (11220/220, which is the national phase of 11220/159)	Patent ZL200510107684.6, granted December 19, 2007.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/221	EP – 02734403.5, filed May 15, 2002 (regional phase of 11220/159)	Allowed in September 2013, Publication No. 1407047.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/237	Hong Kong 05103515.5, filed May 15, 2002  Based on CN Application No. 02815798.2 (11220/220)	Patent No. 1070921, granted November 13, 2009.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/222	Israel – 159301, filed May 15, 2002	Patent No. 159301, granted	Method of determining a chemotherapeutic regimen

Ref. No.	Description/ Application No./Patent No.	Status	Title
		September 17, 2010.	based on glutathione-S-transferase pi expression
11220/223	Japan - 2003-505376, filed May 15, 2002	Patent No. 4303104, granted May 1, 2009.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/281	Japan - 2008-177217, filed July 7, 2008 DIV of 2003-505376 (11220/223)	Patent No. 4308309, granted May 15, 2009.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/224	Korea - 10-2003-7016349, filed May 15, 2002	Patent No. 10-918927, granted September 18, 2009.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/225	Mexico - PA/A/2003/011632, filed May 15, 2002	Patent No. 284095, granted on February 16, 2011.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
11220/226	New Zealand - 530520, filed May 15, 2002	Patent No. 530520, granted February 8, 2007.	Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression

**Patent Family: Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus**

**Foreign cases:**

<b>Ref. No.</b>	<b>Description/ Application No./Patent No.</b>	<b>Status</b>	<b>Title</b>
11220/229	Argentina - P040100598, filed February 26, 2004	Argentine Patent No. AR043398, granted on November 30, 2011.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/228	Taiwan – 93103498, filed February 20, 2004	Patent No. I346701, granted August 11, 2011.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/230	PCT/US2004/004867, filed February 20, 2004	Application Publication No. WO 2004/075833	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/239	Australia – 2004216231, filed February 20, 2004	Patent No. 2004216231, granted November 5, 2009.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/240	Canada – 2517384, filed February 20, 2004	Patent No. 2517384, granted January 22, 2013.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/242	EP – 04713289.9, filed February 20, 2004	Patent No. 1597353, granted November 30, 2011.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/243	Israel – 170217, filed February 20, 2004	Patent No. 170217, granted March 31, 2011.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/245	Korea - 10-2005-7015973, filed February 20, 2004	Korean Patent Number 10-1109062, granted January 17, 2012.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/246	Mexico - PA/A/2005/009162, filed February 20, 2004	Patent No. 280353, granted October 26, 2010.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus
11220/247	New Zealand – 542500, filed February 20, 2004	New Zealand Patent No. 542500, granted August 14, 2008.	Method of Determining a Chemotherapeutic Regimen Based on Loss of Heterozygosity at the Thymidylate Synthase Locus

**Patent Family: KRAS Primers and Probes**

**U.S. Cases:**

<b>Ref. No.</b>	<b>Description/ Application No./Patent No.</b>	<b>Status</b>	<b>Title</b>
11220/300US1	U.S. Application Serial No. 13/640,416  Filed October 10, 2012	Pending. Publication No. 20130029336	KRAS Primers and Probes

**Foreign Cases:**

<b>Ref. No.</b>	<b>Description/ Application No./Patent No.</b>	<b>Status</b>	<b>Title</b>
11220/300	PCT Application No. PCT/US2011/032108, filed April 12, 2011	Application Publication No. WO 2011/130265	KRAS Primers and Probes
11220/300AU1	Australia - Application No. 2011240653, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300CA1	Canada - Application No. Awaiting, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300MX1	Mexico - Application No. MX/A/2012/011698, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300EP1	Europe - Application No. 11730469.1, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300IL1	Israel - Application No. 222379, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300CN1	China - Application No. 2011800219009, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300JP1	Japan - Application No. 2013-505053, filed April 12, 2011	Pending	KRAS Primers and Probes
11220/300KR1	Korea - Application No. 10-2012-7028176, filed April 12, 2011	Pending	KRAS Primers and Probes

Docket Number	Title/Nickname	Country	Serial Number (Filing Date)/ Patent Number (Issue Date)	Status
07017100-5001 US	Knowledge-based Storage of Diagnostic Models "Model Precondition"	US	10/861,177 6/4/2004 8,321,137 11/27/12	Issued 3.5 Year Maintenance Due May 27, 2016
		EP	4789181.7	Abandoned
07017100-5002 US	Systems and Methods for Detecting Biological Features "Likelihood"	US	10/954,443 9/29/2004	Pending Reply to Office Action Due December 19, 2013
07017100-5002-US01 DIV		US-DIV	13/418,991 3/13/12	Pending
		EP	4816896.7	Instructed to abandon
		EP-DIV	11186729.7	Instructed to abandon
		JP	2006-528327	Instructed to abandon
07017100-5002 JP		JP-DIV	2012-820	Pending
07017100-5002 SG		Singapore	200602000-2	Issued Annuity due September 29, 2014
07017100-5003 US	Systems and Methods for Diagnosing A Biological Specimen Using Probabilities "TOO Test"	US	12/378,165 2/10/2009 7,747,547 6/29/2010	Issued 3.5 Year Maintenance Due December 29, 2013
07017100-5004 US	Systems And Methods For Standardization Of Microarray Data "Standardization"	US	12/378,187 2/10/2009 8,473,217 06/25/2013	Issued 3.5 Year Maintenance Due December 25, 2016
07017100-	Systems And Methods For	US	12/705,443	Pending



Docket Number	Title/Nickname	Country	Serial Number (Filing Date)/ Patent Number (Issue Date)	Status
5005 US	Phenotypic Classification Using Biological Samples Of Different Sample Types  "FPTE"		2/10/2010  Confirmation number 8461	

Docket Number	Code	Application Number	Title	Status	Filing Date	Publication No.
39975-020110	US	12/853746	METHODS, PRIMERS, PROBES AND KITS USEFUL FOR THE DETECTION OF BRAF MUTATIONS	Pending	8/10/2010	2011- 0269124A1
39975-022000	PCT	PCT/US2010/44997	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Expired	8/10/2010	WO 2011019704
39975-022100	AR	P100102935	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	AR 077844 9/28/2011
39975-022200	AU	2010282632	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	AU 2010282632 3-8-12
39975-022600	CA	2770716	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	CA 2770716 2/17/2011
39975-022800	CN	201080045765.7	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	CN 102575295 7/11/2012
39975-023500	JP	2012-524782	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	2013-501523 1/17/2013

39975-024200	KR	10-2012-7004699	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	KR 20120099630  9/11/2012
39975-025700	NZ	598166	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	Unpublished
39975-026500	TW	99126740	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	201111517  4/1/2011
39975-026600	IL	218021	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	Unpublished
39975-026700	EP	10808619	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	2464751  6/20/2012
39975-027100	HK	13100094	METHODS, PRIMERS, PROBE & KITS USEFUL FOR THE DETECTION OF BRAF MUTATION	Filed	8/10/2010	Unpublished
39975-032000	PCT	PCT/US11/032694	PRIMERS, PROBES, METHODS AND KITS FOR THE DETECTION OF EML4-ALK MUTATIONS	Inactive	4/15/2011	WO 2011/13065  12/29/2011
39975-032100	AR	P110101303	PRIMERS, PROBES, METHODS AND KITS FOR THE DETECTION OF EML4-ALK MUTATIONS	Filed	4/15/2011	AR 080913  5/16/12
39975-032500	TW	100113162	PRIMERS, PROBES, METHODS AND KITS FOR THE DETECTION OF EML4-ALK MUTATIONS	Filed	4/15/2011	TW 201202703  1/16/12
39975-042000	PCT	PCT/US2012/065877	A NOVEL EML4-ALK VARIANT: PRIMERS, PROBES, METHODS,	Filed	11/19/2012	WO 2013/075110

			AND KITS FOR THE DETECTION THEREOF			7/18/2013
39975-052000	PCT	PCT/US2012/21546	HER3 AND HER4 PRIMERS AND PROBES FOR DETECTING HER3 AND HER4 MRNA	Abandoned		

### Trademarks

Description	Serial Number	Registration Number
Man in a Circle (Design mark)	75915961	2800637
RESPONSE GENETICS	76116173	2800718
RESPONSEDX: TISSUE OF ORIGIN	86107818	Pending
RESPONSEDX: TOO	86062818	Pending
RESPONSE GENETICS & Design	86061652	Pending
RESPONSEDX: MELANOMA	85330476	4207164
RESPONSEDX	77982239	4035760
RESPONSEDX: GASTRIC	77768260	4154436
THE RIGHT THERAPY FOR EACH PATIENT THE FIRST TIME	77587739	3811603
KRAS IS ONLY HALF THE EQUATION	77587737	3886876
RESPONSEDX	77381028	4376661
BECAUSE EVERYONE HAS A DIFFERENT RESPONSE	77386502	3970898
RESPONSEDX: LUNG	77381017	4035279
RESPONSEDX: COLON	77381009	4067404

**Mask Works**

<b>Description</b>	<b>Registration/ Application Number</b>	<b>Registration/ Application Date</b>
NONE		